Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
McKesson
Johnson and Johnson
Harvard Business School
Medtronic

Last Updated: October 13, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,345,315

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,345,315
Title:IGFBP7 for diagnosing diastolic dysfunction
Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.
Inventor(s): Karl; Johann (Peissenberg, DE), Wienhues-Thelen; Ursula-Henrike (Krailling, DE), Block; Dirk (Bichl, DE), Zaugg; Christian (Rheinfelden, CH), Brunner; Hans-Peter (Muenchenstein, CH), Januzzi; James (Wellesley, MA), Ziegler; Andre (Laeufelfingen, CH), Braz; Julian (Greenwood, IN), Dieterle; Thomas (Freiburg, DE), Kaiser; Edelgard (Huenenberg See, CH)
Assignee: Roche Diagnostics Operations, Inc. (Indianapolis, IN)
Application Number:15/274,533
Patent Claims:1. A method for diagnosing and/or grading diastolic dysfunction and/or at least one structural or functional abnormality of the heart associated with diastolic dysfunction in a patient suffering from heart failure, said method comprising the steps of a) obtaining a plasma or serum sample from a human patient suffering from heart failure, b) measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) in the sample from a patient suffering from heart failure, said patient having a reduced left ventricular ejection fraction (LVEF), and c) comparing the level of IGFBP7 measured in a) to a reference level, wherein the structural or functional abnormality associated with diastolic dysfunction is selected from the group consisting of an increased E'/A' ratio, increased left atrial size, increased left atrial volume index, increased E peak velocity, decreased A peak velocity, increased transmitral E/A ratio, increased E/E' ratio, decreased pulmonary vein systolic peak velocity, increased pulmonary vein diastolic peak velocity, decreased pulmonary vein systolic/diastolic ratio, increased right ventricular area, increased right ventricular systolic pressure (RVSP), increased right ventricular dilation, increased right atrium size, a more than mild mitral regurgitation, and a more than mild tricuspid regurgitation, and wherein the level of biomarker is measured using a sandwich immunoassay, and d) administering a drug to treat a diastolic dysfunction and/or at least one structural or functional abnormality associated with diastolic dysfunction, wherein the drug is Spironolactone, Sildenafil and/or Anakinra.

2. The method according to claim 1, wherein the patient suffers from heart failure stage C or D according to ACC/AHA classification, and/or from heart failure NYHA class III or IV according to NYHA classification.

3. The method according to claim 1, wherein the patient has a LVEF of less than 50%.

4. The method of claim 1, wherein the patient has left ventricular hypertrophy.

5. The method of claim 1, wherein the patient suffers from heart failure due to left ventricular systolic dysfunction.

6. The method according to claim 1, wherein diastolic dysfunction and/or at least one structural or functional abnormality associated with diastolic dysfunction is diagnosed, and wherein a) a level of IGFBP7 above the reference level indicates that the patient suffers from diastolic dysfunction and/or said at least one structural or a functional abnormality associated with diastolic dysfunction, and/or b) a level of IGFBP7 below the reference level indicates that the patient does not suffer from diastolic dysfunction and/or said at least one structural or a functional abnormality associated with diastolic dysfunction.

7. The method according to claim 1, wherein diastolic dysfunction and/or at least one structural or functional abnormality associated with diastolic dysfunction is graded, and wherein a) a level of IGFBP7 above the reference level indicates that the patient suffers from a severe form diastolic dysfunction and/or a severe form of said at least one structural or functional abnormality associated with diastolic dysfunction, and/or b) a level of IGFBP7 below the reference level indicates that the patient suffers from a mild form of diastolic dysfunction and/or a mild form of said at least one structural or functional abnormality associated with diastolic dysfunction.

8. The method according to claim 1, wherein the method further comprises the steps: a(i) of measuring the level of at least one further biomarker selected from the group consisting of Osteopontin, a cardiac Troponin, B-type natriuretic peptide (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP), Endostatin, Mimecan, uric acid, and GDF15 (Growth differentiation factor 15) in the sample from the patient, and b(i) comparing the level to a reference level.

9. The method according to claim 1, wherein the patient has a LVEF of less than 40%.

10. The method of claim 1, wherein the patient has a left ventricular mass index larger than 126 g/m2.

Summary for Patent:   See Pricing

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
14161732Mar 26, 2014

Details for Patent 10,345,315

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   See Pricing Roche Diagnostics Operations, Inc. (Indianapolis, IN) 2034-03-26 RX search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14   See Pricing Roche Diagnostics Operations, Inc. (Indianapolis, IN) 2034-03-26 RX search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 003 2001-11-14   See Pricing Roche Diagnostics Operations, Inc. (Indianapolis, IN) 2034-03-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,345,315

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2015144767 Oct 01, 2015
United States of America 2017010283 Jan 12, 2017
Japan 2017512988 May 25, 2017
Japan 6535021 Jun 26, 2019
Spain 2676553 Jul 20, 2018
European Patent Office 2924438 Apr 18, 2018
European Patent Office 2924438 Sep 30, 2015
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Dow
AstraZeneca
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.